

Overview: 5th Edition Paediatric STGs and EML

Mr A Gray

Session 2

NEW RELEASE

The updated Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML), 2023 (5th Edition) have been released

The Paediatric Hospital Level Standard Treatment Guidelines (STGs) and Essential Medicines List (EML) aim to provide equitable access to good quality healthcare for all children.

**Standard Treatment Guidelines
and Essential Medicines List
for South Africa**

PAEDIATRIC HOSPITAL LEVEL
2023 EDITION

Accessing 2023 Edition

- The 5th Edition of the Paediatric Hospital Level STGs and EML can be downloaded from the following website: <https://knowledgehub.health.gov.za/content/standard-treatment-guidelines-and-essential-medicines-list>
- Additionally, all updated chapters have been loaded on the EMGuidance mobile application: To sign up, click on the link: <http://onelink.to/sy896k>



Paediatric Hospital Level STGs and EML

- This latest edition of the Paediatric Hospital Level STGs and EML is a culmination of many efforts from a broad range of experts.

Paediatric Hospital Level Expert Review Committee

Mr A Gray (Chairperson)
Dr G Reubenson (Vice Chairperson)
Dr M Archary
Dr A Bhetray

Prof P Jeena
Dr N Lala
Dr T Ruder

Co-opted consultants to the Paediatric Expert Review Committee

Dr P Ambaram
Dr K Balme
Dr C Hlela
Mr A Hohlfeld
Dr D Kloeck
Dr S Kubheka
Dr J Lawrenson

Prof R Mathivha
Dr M Meiring
Dr H Naidoo
Dr KD Naidoo
Dr S Paruk
Mr H Sablay
Dr C Stephens

National Essential Medicines List Committee

And Stakeholder Comments and Contributions

Feedback and Collaboration



- Review of the STGs and EML is a dynamic process.
- Encourage the continued:
 - ✓ engagement,
 - ✓ feedback, and
 - ✓ collaboration from all healthcare stakeholders
- Constructive comment is encouraged.

Pain Management in Children

- Management of pain is an area the Expert Review Committee spent a great deal of time deliberating over.
- Complexities considered included:
 - **Assessment of pain**
 - **Product availability**
 - **Appropriate dosage forms**
 - **Safety**



Session 2 will talk to some of these complexities and the recommendations made in the updated guidance

Thank you